DI
Therapeutic Areas
CNBX Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Cannabics® RCC-33 | Colorectal Cancer | Preclinical |
| Cannabics® MLN-33 | Melanoma | Discovery |
| Cannabics® BRST-33 | Breast Cancer | Discovery |
| Cannabics® PRST-33 | Prostate Cancer | Discovery |
| Cannabics® PLP-33 | Pre-cancerous Polyps | Preclinical |
| Cannabics® SR | Cancer-related Anorexia Cachexia Syndrome (CACS) | Phase 3 |
| NP-01 | Neuropsychiatry (Unspecified) | Discovery |
| NP-02 | Neuropsychiatry (Unspecified) | N/A |
Leadership Team at CNBX Pharmaceuticals
GY
Gabriel Yariv
Executive Chairman of the Board
EB
Eyal Barad
Co-Founder, CEO, Board Member
DG
Dr. Gil Feiler
Independent Board Member, Head of Advisory Board
SY
Shaul Yemal
Independent Board Member
UB
Uri Ben-Or
CFO
DS
Dr. Sanja Goldberg
CTO
DI
Dr. Ilya Reznik
Head of Neuropsychiatry Development
DL
Dr. Lior Eshdat
VP Intellectual Property